SABCS 2022

SABCS 2022
December 06-10, 2022
San Antonio, TX

San Antonio Breast Cancer Symposium 2022.

Explore more information for Gilead Oncology therapies
Results (4)

Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in HR+/HER2- metastatic breast cancer

A phase 2, randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triplenegative breast cancer (TiP)

Effect of sacituzumab govitecan vs chemotherapy in HR+/HER2- metastatic breast cancer: patient-reported outcomes from the TROPiCS-02 trial

Sacituzumab Govitecan vs Treatment of Physician's Choice: Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients With HR+/HER2- Metatatic Breast Cancer